Upregulation of POC1A in lung adenocarcinoma promotes tumour progression and predicts poor prognosis
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Zi-Hao Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Applied Project of Guangxi Health and Medical Appropriate Technology in Development and Promotion.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) is characterized by a high incidence rate and mortality. Recently, POC1 centriolar protein A (POC1A) has emerged as a potential biomarker for various cancers, contributing to cancer onset and development. However, the association between POC1A and LUAD remains unexplored. We extracted The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) data sets to analyse the differential expression of POC1A and its relationship with clinical stage. Additionally, we performed diagnostic receiver operator characteristic (ROC) curve analysis and Kaplan–Meier (KM) survival analysis to assess the diagnostic and prognostic value of POC1A in LUAD. Furthermore, we investigated the correlation between POC1A expression and immune infiltration, tumour mutation burden (TMB), immune checkpoint expression and drug sensitivity. Finally, we verified POC1A expression using real‐time quantitative polymerase chain reaction (RT‐qPCR) and immunohistochemistry (IHC). Cell experiments were conducted to validate the effect of POC1A expression on the proliferation, migration and invasion of lung cancer cells. POC1A exhibited overexpression in most tumour tissues, and its overexpression in LUAD was significantly correlated with late‐stage presentation and poor prognosis. The high POC1A expression group showed lower levels of immune infiltration but higher levels of immune checkpoint expression and TMB. Moreover, the high POC1A expression group demonstrated sensitivity to multiple drugs. In vitro experiments confirmed that POC1A knockdown led to decreased proliferation, migration, and invasion of lung cancer cells. Our findings suggest that POC1A may contribute to tumour development by modulating the cell cycle and immune cell infiltration. It also represents a potential therapeutic target and marker for the diagnosis and prognosis of LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- Geriatrics Department of Endocrinology and Metabolism, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
- Department of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
ORCID-Profile: Xiao-Chun Zeng
Förderung
- Applied Project of Guangxi Health and Medical Appropriate Technology in Development and Promotion
Zitieren
APA
Li, Z. H., Li, J. Y., Wu, Z. T., Zhu, Y. J., Zhuo, T., Nong, J. S., Qian, J., Peng, H. J., Dai, L., Wang, Y. Y., Chen, M. W., & Zeng, X. C. (2024). Upregulation of POC1A in lung adenocarcinoma promotes tumour progression and predicts poor prognosis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18135
Vancouver
Li ZH, Li JY, Wu ZT, Zhu YJ, Zhuo T, Nong JS, et al. Upregulation of POC1A in lung adenocarcinoma promotes tumour progression and predicts poor prognosis. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18135
BibTeX
@article{Li2024,
author = {Li, Zi-Hao and Li, Jia-Yi and Wu, Zuo-Tao and Zhu, Yong-Jie and Zhuo, Ting and Nong, Ju-Sen and Qian, Jing and Peng, Hua-Jian and Dai, Lei and Wang, Yong-Yong and Chen, Ming-Wu and Zeng, Xiao-Chun},
title = {Upregulation of POC1A in lung adenocarcinoma promotes tumour progression and predicts poor prognosis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18135}
}
EUVIMED